- Home
- INKT vs COEP Comparison
INKT vs COEP Comparison
Compare INKT & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- COEP
- Stock Information
- Founded
- INKT 2017
- COEP 2017
- Country
- INKT United States
- COEP United States
- Employees
- INKT N/A
- COEP N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INKT Health Care
- COEP Health Care
- Exchange
- INKT Nasdaq
- COEP Nasdaq
- Market Cap
- INKT 28.8M
- COEP 27.4M
- IPO Year
- INKT 2021
- COEP N/A
- Fundamental
- Price
- INKT $28.86
- COEP $9.81
- Analyst Decision
- INKT Hold
- COEP
- Analyst Count
- INKT 3
- COEP 0
- Target Price
- INKT $37.50
- COEP N/A
- AVG Volume (30 Days)
- INKT 2.7M
- COEP 37.8K
- Earning Date
- INKT 08-12-2025
- COEP 08-15-2025
- Dividend Yield
- INKT N/A
- COEP N/A
- EPS Growth
- INKT N/A
- COEP N/A
- EPS
- INKT N/A
- COEP N/A
- Revenue
- INKT N/A
- COEP $62,874.00
- Revenue This Year
- INKT N/A
- COEP N/A
- Revenue Next Year
- INKT N/A
- COEP N/A
- P/E Ratio
- INKT N/A
- COEP N/A
- Revenue Growth
- INKT N/A
- COEP N/A
- 52 Week Low
- INKT $4.56
- COEP $2.31
- 52 Week High
- INKT $76.00
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- INKT 60.80
- COEP 65.80
- Support Level
- INKT $6.80
- COEP $7.25
- Resistance Level
- INKT $76.00
- COEP $9.90
- Average True Range (ATR)
- INKT 5.95
- COEP 0.57
- MACD
- INKT 3.73
- COEP 0.30
- Stochastic Oscillator
- INKT 35.31
- COEP 100.00
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.